{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:07:23Z","timestamp":1789103243707,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The impact of healthcare-related time intervals on outcomes in bone sarcomas remains controversial. We evaluated the impact of clinically defined post-referral, in-hospital care intervals on overall survival (OS) and their variation over two decades, in patients treated at a tertiary sarcoma centre. Methods: We retrospectively analysed 506 patients with localized osteosarcoma (n = 319) or Ewing\u2019s sarcoma (n = 187) treated between 2002 and 2021. We defined three in-hospital time intervals: time to diagnosis (TToD; first specialist evaluation to diagnostic biopsy), time to treatment (TToT; biopsy to treatment initiation), and total post-referral patient journey time (PJT; first specialist evaluation to treatment). Multivariable Cox models adjusted for age, sex, tumour location, and surgical factors evaluated associations with OS. Results: Median PJT was longer in Ewing\u2019s sarcoma than in osteosarcoma (17 vs. 14 days; p &lt; 0.001), mainly because of a longer TToT. Over time, median PJT increased from 12 to 19 days (p &lt; 0.001), driven by longer TToT, while TToD remained stable. Neither PJT nor TToD was associated with OS. Although longer TToT was associated with lower mortality risk, this was not confirmed after stratification by diagnostic period. Worse OS was independently associated with amputation, upper-extremity tumours, and intralesional margins. Conclusions: Within the specialized tertiary centre setting, longer in-hospital care timelines were not associated with poorer overall survival despite increasing over time, a finding that may reflect the growing complexity of multidisciplinary management exclusively during the post-referral phase.<\/jats:p>","DOI":"10.3390\/cancers18182927","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:43:16Z","timestamp":1788972196000},"page":"2927","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Clinical Time Intervals Along the Patient Journey with Overall Survival in Localized Osteosarcoma and Ewing Sarcoma: A 20-Year Tertiary Sarcoma Centre Experience"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-9694","authenticated-orcid":false,"given":"Roberta","family":"Laranga","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-5085","authenticated-orcid":false,"given":"Cristina","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology Research and Functional Genomics, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zuccheri","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Clementi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-9762","authenticated-orcid":false,"given":"Giuseppe","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"},{"name":"Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing Sarcoma: Current Management and Future Approaches through Collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fukushima, T., Ogura, K., Akiyama, T., Takeshita, K., and Kawai, A. (2018). Descriptive Epidemiology and Outcomes of Bone Sarcomas in Adolescent and Young Adult Patients in Japan. BMC Musculoskelet. Disord., 19.","DOI":"10.1186\/s12891-018-2217-1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.9-4-422","article-title":"Biology and Therapeutic Advances for Pediatric Osteosarcoma","volume":"9","author":"Marina","year":"2004","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(09)70286-4","article-title":"Ewing\u2019s Sarcoma","volume":"11","author":"Balamuth","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2022.03.001","article-title":"The Gap between Rare and Common Cancers Still Exists: Results from a Population-Based Study in the Netherlands","volume":"167","author":"Duijts","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing Therapy for Osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E508","DOI":"10.1002\/ijc.26426","article-title":"Incidence and Survival of Malignant Bone Sarcomas in England 1979\u20132007","volume":"131","author":"Whelan","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100281","DOI":"10.1016\/j.jbo.2020.100281","article-title":"Prognostic Factors in Osteosarcoma: A Study Level Meta-Analysis and Systematic Review of Current Practice","volume":"21","author":"Xin","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ijc.34694","article-title":"Twenty-Year Outcome of Prevalence, Incidence, Mortality and Survival Rate in Patients with Malignant Bone Tumors","volume":"154","author":"Xu","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ctrv.2013.11.006","article-title":"Osteosarcoma Treatment\u2014Where Do We Stand? A State of the Art Review","volume":"40","author":"Luetke","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s11864-024-01269-2","article-title":"Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma","volume":"25","author":"Robinson","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hesla, A.C., Papakonstantinou, A., and Tsagkozis, P. (2021). Current Status of Management and Outcome for Patients with Ewing Sarcoma. Cancers, 13.","DOI":"10.3390\/cancers13061202"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ferrari, C., Magagnoli, G., Laranga, R., Bianchi, G., Carretta, E., Cesari, M., Scotlandi, K., Baldini, N., Donati, D.M., and Gambarotti, M. (2025). Osteosarcoma and Ewing Sarcoma of Bone: An Italian Mono-Institutional Epidemiological Study. Diagnostics, 15.","DOI":"10.3390\/diagnostics15030328"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and Prognosis with Osteosarcoma: Outcomes in More than 2000 Patients in the EURAMOS-1 (European and American Osteosarcoma Study) Cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2013.53.8058","article-title":"Time to Diagnosis of Ewing Tumors in Children and Adolescents Is Not Associated with Metastasis or Survival: A Prospective Multicenter Study of 436 Patients","volume":"32","author":"Brasme","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/sj.bjc.6605384","article-title":"Do Diagnostic Delays in Cancer Matter?","volume":"101","author":"Neal","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ciechanowicz, D., Kotrych, D., Starszak, K., Prowans, P., Zacha, S., Kami\u0144ski, A., Brodecki, A., and Kotrych, K. (2025). Delay in Diagnosis and Treatment of Bone Sarcoma\u2014Systematic Review. Cancers, 17.","DOI":"10.3390\/cancers17060981"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality Due to Cancer Treatment Delay: Systematic Review and Meta-Analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13569-016-0047-1","article-title":"UK Guidelines for the Management of Bone Sarcomas","volume":"6","author":"Gerrand","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2012.68","article-title":"The Aarhus Statement: Improving Design and Reporting of Studies on Early Cancer Diagnosis","volume":"106","author":"Weller","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_23","unstructured":"Schwab, M. (2020, December 15). IARC Publications Website\u2014Pathology and Genetics of Tumours of Soft Tissue and Bone. Available online: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Pathology-And-Genetics-Of-Tumours-Of-Soft-Tissue-And-Bone-2002."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"Bone Sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/bjc.2015.48","article-title":"Is Increased Time to Diagnosis and Treatment in Symptomatic Cancer Associated with Poorer Outcomes? Systematic Review","volume":"112","author":"Neal","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1357","article-title":"Immortal Time Bias in Observational Studies of Drug Effects","volume":"16","author":"Suissa","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft Tissue and Visceral Sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2606","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/14737140.8.4.617","article-title":"Ewing Sarcoma: Prognostic Criteria, Outcomes and Future Treatment","volume":"8","author":"Leavey","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF01197769","article-title":"New Method of Evaluating the Surgical Margin and Safety Margin for Musculoskeletal Sarcoma, Analysed on the Basis of 457 Surgical Cases","volume":"121","author":"Kawaguchi","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.21037\/tcr-20-2187","article-title":"Regional Lymph Node Involvement Is Associated with Poorer Survivorship in Patients with Upper Extremity Osteosarcoma than with Lower Extremity Osteosarcoma: A SEER Analysis","volume":"9","author":"Xie","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1245\/s10434-009-0825-6","article-title":"Differential Presentations, Clinical Courses, and Survivals of Osteosarcomas of the Proximal Humerus over Other Extremity Locations","volume":"17","author":"Cho","year":"2010","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:28:56Z","timestamp":1789100936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":31,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182927"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182927","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}